Lessons Learned. Pregabalin is a medication that can decrease neuronal hyperexcitability, relieve neuropathic pain, and reach stable plasma levels after a titration period of only a few days.Its use during oxaliplatin infusions was not able to decrease the incidence of chronic, oxalipaltin‐related neuropathic pain, compared with placebo.Background.Patients with colorectal cancer (CRC) receiving oxaliplatin (OXA) develop acute and chronic painful oxaliplatin‐induced peripheral neuropathy (OXAIPN). Acute and chronic OXA‐related neuropathies have different pathophysiological bases, but both lead to a common phenomenon: central sensitization (CS) of nociceptive neuronal networks, leading to increased sensitivity (hyperlgesia, allodynia) in the somatosensory system, the common ground of chronic neuropathic pain. Because CS is related to increased risk of painful OXAIPN, we hypothesized that preemptive use of the anti‐hyperalgesic drug pregabaline (known to decrease CS) during OXA infusions would decrease the incidence of chronic OXAIPN.Methods.Pain‐free, chemotherapy‐naïve CRC patients receiving at least one cycle of modified‐FLOX [5‐FU(500 mg/m2)+leucovorin(20 mg/m2)/week for] 6 weeks+oxaliplatin(85 mg/m2) at weeks 1‐3‐5 every 8 weeks] were randomized (1:1) into the study. Patients received either pregabalin or placebo for 3 days before and 3 days after each OXA infusion and were followed for up to 6 months. Clinical assessments were performed at baseline, at the end of chemotherapy, and after the follow‐up period. The main outcome was average pain at the last visit assessed by the visual analogic scale (0–10) item of the Brief Pain Inventory (BPI). Secondary endpoints were presence of neuropathic pain according to the Douleur Neuropathique‐4 (DN‐4), pain dimensions (short‐ form McGill Pain Questionnaire [MPQ]), Neuropathic Pain Symptom Inventory (NPSI), and changes in nerve conduction studies (NCS) and side effect profile.Results.One hundred ninety‐nine patients (57.0 ± 10.7 years old, 98 female, 101 male) were randomized. Data from 56 patients were not included in the analyses (as they did not receive at least one full cycle of modified FLOX). Data from 78 patients in the pregabalin group and 65 patients in the placebo group were retained for analyses. At the last visit, pain intensity in the pregabalin group was 1.03 (95% confidence interval [CI] = 0.79–1.26), and 0.85 (95% CI = 0.64–1.06) in the placebo group, which did not reach significance. Scores from the BPI, MPQ, DN‐4, NPSI, and NCS and side‐effect profiles and incidence of death did not differ between groups. Quality of life (QoL) score did not differ between groups (placebo = 76.9 ± 23.1, pregabalin group 79.4 ± 20.6). Mood scores were not significantly different between groups (placebo 9.7 [8.1–11.2]; pregabalin 6.8 [5.6–8.0]).Conclusion.The preemptive use of pregabalin during OXA infusions was safe, but did not decrease the incidence of chronic pain related to OXAIPN.

doi: 10.5216/ree.v12i3.6957O constructo subjetivo e multidimensional Qualidade de Vida (QV) consolida-se entre os estudiosos na década de 90. Identificar, mensurar e avaliar os domínios afetados pela doença tem sido a proposta de diversos estudos com delineamentos qualitativos e quantitativos. Os objetivos foram caracterizar a produção científica latinoamericana sobre QV em pacientes oncológicos adultos; identificar aspectos relacionados à QV nesta população; identificar os instrumentos utilizados para avaliar a QV. Uma das estratégias metodológicas para realizar a prática baseada em evidências é a revisão integrativa. A amostra resultou em 25 artigos, nos quais havia uma alta concentração de estudos na subcategoria QV nos diferentes tipos de câncer de cabeça e pescoço (32%), que nos faz refletir sobre os inúmeros efeitos colaterais e secundários do tratamento, como as mutilações, alterações funcionais e estéticas que interferem nas atividades de vida diária dos pacientes. Verificamos uma prevalência na aplicação do instrumento EORTC QLQ-C30 sendo que este explora sintomas específicos do câncer. Considera-se que tais estudos não apresentaram fortes evidências para aplicação clínica. Correspondendo a prática baseada em evidências, concluímos a importância no desenvolvimento de estudos com intervenções efetivas para subsidiar a prática de enfermagem e garantir uma assistência qualificada e consequentemente melhorar QV aos pacientes oncológicos. Descritores: Neoplasias; Qualidade de vida; Enfermagem Oncológica.

RESUmoUma das estratégias metodológicas para realizar a prática baseada em evidências é a revisão integrativa, que neste estudo teve como objetivo buscar e sintetizar as evidências disponíveis na literatura científica sobre os fatores de riscos alimentares para o câncer colorretal relacionado ao consumo de carnes. As bases de dados LILACS, MEDLINE, CINAHL e COCHRANE Library foram consultadas e os estudos pertinentes ao consumo de carnes somaram-se seis. As metanálises demonstraram que a ingestão de carne vermelha está relacionada com o aumento do risco para câncer colorretal em 28% a 35%, enquanto que a carne processada está associada ao risco elevado de 20% a 49%. As evidências apontam a carne vermelha, a carne processada e o total de carne consumida como fatores de risco para o desenvolvimento de pólipos e cân-cer colorretal. Não foi identificado estudo que indicasse a ingestão de frango e peixe como fatores de risco. dEScRiToRES Neoplasias colorretais Fatores de risco Carne Enfermagem oncológica AbSTRAcTThe integrative review is one of the methodologies used for evidence-based practice which, in this study, had the objective of surveying and synthesizing the evidence available in the literature regarding the dietary risks for colorectal cancer related to the consumption of meat. The search was made using the LILACS, MEDLINE, CINAHL, and COCHRANE Library databases, and six studies considered pertinent to the consumption of meat were found. Meta-analyses showed that there is an association between the consumption of red meat and an increased risk for colorectal cancer from 28% to 35%, whereas processed meats are associated with a rise in risk from 20% to 49%. Evidence shows that the consumption of red meat, processed meat, and total meat consumption are risk factors for developing polyps and colorectal cancer. The search did not yield any studies referring to the consumption of chicken or fish as risk factors. dEScRiPToRS Colorectal neoplasms Risk factors Meat Oncologic nursing RESUmEnUna de las estrategias metodológicas para realizar la práctica basada en evidencias es la revisión integradora, que en este estudio objetivó buscar y sintetizar las evidencias disponibles en literatura científica sobre factores de riesgo alimentario para desarrollar cáncer colorrectal en relación al consumo de carne. Se consultaron las bases de datos LILACS, MEDLINE, CINAHL y COCHRANE Library, y los estudios pertinentes al consumo de carnes sumaron seis. Los metanálisis demostraron que la ingestión de carne roja está relacionada con el aumento de riesgo de cáncer colorrectal en 28% a 35%, mientras que la carne procesada se relaciona con un riesgo aumentado entre 20% y 49%. Las evidencias exponen a la carne roja, la carne procesada y al total de carne consumida como factores de riesgo para desarrollo de pólipos y cáncer colorrectal. No existió evidencia que relacionara la ingesta de pollo y pescado como factores de riesgo. dEScRiPToRESNeoplasias colorrectales